203/212Pb-DOTA-based pretargeted radioimmunotherapy against the glycoprotein GPA33 antigen. (IMAGE)

Society of Nuclear Medicine and Molecular Imaging

203/212Pb-DOTA-based pretargeted radioimmunotherapy against the glycoprotein GPA33 antigen.

Caption

203/212Pb-DOTA-based pretargeted radioimmunotherapy against the glycoprotein GPA33 antigen is safe and effective in preclinical models of human colorectal cancer. 

Credit

Image created by Department of Communications, Design and Creative Services, Memorial Sloan Kettering Cancer Center, New York, NY.

Usage Restrictions

Please give appropriate credit.

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.